We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-7.07%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$393M
AUM Growth
-$29.9M
Cap. Flow
+$15.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
52.55%
Holding
90
New
6
Increased
29
Reduced
20
Closed
8

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$5.71M
2
TELA icon
TELA Bio
TELA
+$4.05M
3
KROS icon
Keros Therapeutics
KROS
+$2.94M
4
BPMC
Blueprint Medicines
BPMC
+$2.56M
5
BCAX
Bicara Therapeutics
BCAX
+$2.2M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$3.48M
2
SLRN
ACELYRIN
SLRN
+$2.49M
3
AQST icon
Aquestive Therapeutics
AQST
+$2.13M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$1.3M
5
AXGN icon
Axogen
AXGN
+$1.26M

Sector Composition

Rank Sector Weight
1 Healthcare 86.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
76
Black Diamond Therapeutics
BDTX
$110M
$300K 0.08%
140,000
+15,000
+12% +$43K
PHGE icon
77
BiomX
PHGE
$1.72M
$293K 0.07%
21,112
– –
SLRN
78
DELISTED
ACELYRIN
SLRN
$276K 0.07%
87,989
-514,905
-85% -$2.49M
CMPX icon
79
Compass Therapeutics
CMPX
$358M
$230K 0.06%
158,394
+41,512
+36% +$68.9K
NVRO
80
DELISTED
NEVRO CORP.
NVRO
$141K 0.04%
38,000
– –
SPRO icon
81
Spero Therapeutics
SPRO
$73.5M
$129K 0.03%
125,000
– –
ADAP
82
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-341,064
Closed -$324K
KPTI icon
83
Karyopharm Therapeutics
KPTI
$44.2M
– –
-12,845
Closed -$160K
NYXH
84
Nyxoah
NYXH
$131M
– –
-108,108
Closed -$1.03M
STIM icon
85
Neuronetics
STIM
$157M
– –
-313,717
Closed -$238K
TRML
86
DELISTED
Tourmaline Bio
TRML
– –
-19,110
Closed -$491K
VSTM icon
87
Verastem
VSTM
$519M
– –
-127,700
Closed -$382K
ANRO icon
88
Alto Neuroscience
ANRO
$1.11B
– –
-26,786
Closed -$306K
GRAL
89
GRAIL Inc
GRAL
$2.72B
– –
-48,800
Closed -$671K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, DAFNA Capital Management held 90 positions worth $393M, down 7.1% from $423M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $15.9M of net new capital in Q4 2024, opening 6 new positions and adding to 29 existing holdings. Its largest new stake was TELA Bio: 1,441,029 shares worth $4.35M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier.

On the sell side, the largest reduction was Viking Therapeutics, an estimated $3.48M trimmed.

  • DAFNA Capital Management's largest Q4 2024 buy was TELA Bio: 1,441,029 shares worth $4.35M.
  • DAFNA Capital Management added most to Revolution Medicines in Q4 2024, an estimated $5.71M increase.
  • DAFNA Capital Management's biggest Q4 2024 reduction was Viking Therapeutics, cutting an estimated $3.48M.
  • DAFNA Capital Management fully exited Nyxoah in Q4 2024, selling an estimated $1.03M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $393M portfolio in Q4 2024.
  • DAFNA Capital Management opened 6 new positions and closed 8 in Q4 2024.
  • DAFNA Capital Management's portfolio value fell 7.1% quarter-over-quarter to $393M.

Based on DAFNA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.